查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年歐洲傳染病治療市場預測 - 區域分析 - 按藥物類別、適應症、給藥途徑和配銷通路
市場調查報告書
商品編碼
1562256

2030 年歐洲傳染病治療市場預測 - 區域分析 - 按藥物類別、適應症、給藥途徑和配銷通路

Europe Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route Of Administration, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 106 Pages | 訂單完成後即時交付

價格

2022年歐洲傳染病治療市值為354.5186億美元，預計2030年將達到491.0821億美元；預計2022年至2030年複合年成長率為4.2%。

對傳染病治療的資金和研發的日益關注推動了歐洲傳染病治療市場

研究與開發（R&D）是生物製藥和製藥公司業務的重要組成部分。研發使他們能夠推出具有巨大醫療和商業潛力的多種治療應用的新產品。此外，領先的市場參與者正在投資研發，以開發增強的技術並獲得更多的收入佔有率。

為了為歐洲和世界其他地區目前遇到的最重要的健康問題找到解決方案，歐盟正在投資研究、技術和創新。歐盟委員會在促進研究方面發揮了領導作用，特別是與傳染病免疫和管理相關的研究。 2007 年至 2019 年間，超過 43 億美元（40 億）撥款用於傳染病研究。此外，地平線歐洲，即將推出的（2021-2027年）歐盟研究和創新（R＆I）資助計劃，將繼續支持傳染病的R＆I，特別是那些與貧困有關的疾病，那些被忽視的疾病，以及那些（重新） ）出現。

Horizo​​n Europe 是一個致力於支持研究和創新的計劃。為了彌合跨地區障礙並建立切實的合作，該計畫非常重視確保大學、科學界、工業界（特別是中小企業）和個人之間的合作。衛生工作計畫概述了地平線歐洲下針對傳染病和大流行病防備和應對相關研究的資助方案。因此，對傳染病治療的研發和資金的日益關注推動了傳染病治療市場的成長。

歐洲傳染病治療市場概況

歐洲傳染病治療市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。歐洲在全球傳染病治療市場中佔有重要地位，預計 2022-2030 年複合年成長率顯著。該地區慢性病毒性疾病發生率上升，對開發新型抗病毒藥物的需求很高。歐洲在 2007 年至 2019 年透過第七框架計畫和地平線 2020 資助了 157.9 億美元，並承諾為 COVID-19 研究提供 11 億美元，在資助和協調傳染病研究方面發揮著至關重要的作用。據羅伯特·科赫研究所稱，在德國，每年約有40萬至60萬名患者遭受院內感染，其中1萬至1.5萬人死亡。醫療保健提供者面臨的典型問題是手術部位感染、泌尿道感染和肺炎。德國對抗感染藥物的需求正在顯著成長，原因是老年人口不斷增加、慢性病毒性疾病患病率不斷增加，以及為病毒治療領域生產新分子以滿足未滿足條件的需求不斷成長。德國因其成品的高品質而成為歐洲抗病毒藥物生產和成長潛力的領先國家之一。例如，生物製藥公司 Atriva Therapeutics GmbH 在一項旨在阻止 SARS-CoV-2 病毒傳播的 II 期研究中開發了 ATR-002，用於治療 COVID-19 患者。因此，由於上述因素，預計該國市場將大幅成長。

歐洲傳染病治療市場收入及 2030 年預測（百萬美元）

歐洲傳染病治療市場細分

歐洲傳染病治療市場按藥物類別、適應症、給藥途徑、配銷通路和國家分類。

依藥物類別，歐洲傳染病治療市場分為抗病毒、抗細菌、抗真菌等。 2022 年，抗病毒藥物領域佔據最大的市場佔有率。

從適應症來看，歐洲傳染病治療市場分為愛滋病毒、肝炎、結核病、流感、HPV等。 2022 年，HIV 佔據最大的市場佔有率。

依給藥途徑，歐洲傳染病治療市場分為口服、腸胃外、外用等。 2022 年，口腔細分市場佔據最大的市場。

從配銷通路來看，歐洲傳染病治療市場分為醫院藥局、零售藥局等。 2022年，醫院藥局佔最大的市場佔有率。

依國家/地區分類，歐洲傳染病治療市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。 2022 年，德國在歐洲傳染病治療市場佔有率中佔據主導地位。

AbbVie Inc、Astellas Pharma Inc、Bayer AG、BioCryst Pharmaceuticals Inc、F. Hoffmann-La Roche Ltd、Gilead Sciences Inc、GSK Plc、Merck & Co Inc、Pfizer Inc 和 Shionogi & Co Ltd 是在歐洲傳染病治療市場。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：歐洲傳染病治療市場 - 主要市場動態

  • 歐洲傳染病治療市場 - 主要市場動態
  • 市場促進因素
    • 傳染病病率上升
    • 越來越關注傳染病治療的經費與研發
  • 市場限制
    • 抗感染藥物抗藥性的出現及相關副作用
  • 市場機會
    • 抗生素抗藥性威脅不斷升級
  • 未來趨勢
    • 產品批准和發布數量不斷增加
  • 促進因素和限制的影響：

第 5 章：傳染病治療市場 - 歐洲分析

  • 2022-2030年歐洲傳染病治療市場收入

第 6 章：歐洲傳染病治療市場分析 - 按藥物類別

  • 概述
  • 抗病毒劑
  • 抗菌
  • 抗真菌
  • 其他

第 7 章：歐洲傳染病治療市場分析 - 按適應症

  • 概述
  • 愛滋病
  • 肝炎
  • 結核
  • 流感
  • HPV病毒
  • 其他

第 8 章：歐洲傳染病治療市場分析 - 按給藥途徑

  • 概述
  • 口服
  • 注射用
  • 專題
  • 其他

第 9 章：歐洲傳染病治療市場分析 - 按配銷通路

  • 概述
  • 醫院藥房
  • 零售藥局
  • 其他

第 10 章：歐洲傳染病治療市場 - 國家分析

  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區

第 11 章：傳染病治療市場-產業格局

  • 概述
  • 傳染病治療市場的成長策略
  • 無機成長策略
    • 概述
  • 有機成長策略
    • 概述

第 12 章：公司簡介

  • Pfizer Inc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Shionogi & Co Ltd
  • Bayer AG
  • BioCryst Pharmaceuticals Inc
  • GSK Plc
  • AbbVie Inc
  • Merck & Co Inc
  • Astellas Pharma Inc

第 13 章：附錄

Product Code: BMIRE00030411

The Europe infectious disease therapeutics market was valued at US$ 35,451.86 million in 2022 and is expected to reach US$ 49,108.21 million by 2030; it is estimated to register a CAGR of 4.2% from 2022 to 2030.

Increasing Focus on Funding and R&D in Infectious Disease Therapeutics Drives Europe Infectious Disease Therapeutics Market

Research and development (R&D) is a critical part of the business of biopharmaceuticals and pharmaceutical companies. R&D enables them to launch new products for several therapeutic applications with significant medical and commercial potential. Also, leading market players are investing in R&D to develop enhanced technologies and gain more revenue share.

In order to create solutions for the most important health issues that Europe and the rest of the world are currently encountering, the European Union is investing in research, technology, and innovation. The European Commission has led the way in promoting research, particularly that related to immunity to and management of infectious diseases. Between 2007 and 2019, more than US$ 4.3 billion (4 billion) was allocated to the study of infectious diseases. Further, Horizon Europe, the upcoming (2021-2027) EU funding initiative for research and innovation (R&I), will carry on supporting R&I for infectious diseases, notably those associated with poverty, those that are neglected, and those that are (re-)emerging.

Horizon Europe is a program dedicated to supporting research and innovation. To bridge barriers across regions and establish tangible collaborations, the program places a strong emphasis on ensuring cooperation between universities, scientific communities, industry, especially small and medium-sized firms, and individuals. The Health Work Programme outlines funding options under Horizon Europe for research related to infectious diseases and pandemic preparedness and response. Thus, rising focus on R&D and funding in infectious disease therapeutics drive the infectious disease therapeutics market growth.

Europe Infectious Disease Therapeutics Market Overview

The Europe infectious disease therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global infectious disease therapeutics market and is estimated to register a notable CAGR during 2022-2030. The region has an increased incidence of chronic viral diseases and a high demand for developing new anti-viral drugs. With US$ 15.79 billion funded from 2007 to 2019 through the 7th Framework Program and Horizon 2020 and the US$ 1.1 billion pledged for COVID-19 research, Europe plays a crucial role in funding and coordinating research on infectious diseases. According to The Robert Koch Institute, in Germany, ~400,000 to 600,000 patients suffer a hospital-acquired infection each year, among which 10,000-15,000 die. Typical problems for healthcare providers are surgical site infections, urinary tract infections, and pneumonia. The demand for anti-infective agents in Germany is growing significantly, attributed to the rising geriatric population, the increasing prevalence of chronic viral diseases, and the growing demand to produce new molecules for viral therapeutic areas to fulfill unmet conditions. Germany is one of the leading nations for anti-viral agent manufacturing and growth potential in Europe due to the high quality of its finished products. For instance, Atriva Therapeutics GmbH, a biopharmaceutical company, developed ATR-002 to treat patients with COVID-19 in a Phase II Study to block viral propagation of SARS-CoV-2. Therefore, due to the abovementioned factors, the market is expected to grow significantly in the country.

Europe Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Europe Infectious Disease Therapeutics Market Segmentation

The Europe infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the Europe infectious disease therapeutics market is segmented into anti-viral, anti bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the Europe infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the Europe infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the Europe infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the Europe infectious disease therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the Europe infectious disease therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Infectious Disease Therapeutics Market - Key Market Dynamics

  • 4.1 Europe Infectious Disease Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Infectious Disease
    • 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
  • 4.4 Market Opportunities
    • 4.4.1 Escalating Threat of Antibiotic Resistance
  • 4.5 Future Trends
    • 4.5.1 Rising Number of Product Approvals and Launches
  • 4.6 Impact of Drivers and Restraints:

5. Infectious Disease Therapeutics Market - Europe Analysis

  • 5.1 Europe Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

6. Europe Infectious Disease Therapeutics Market Analysis - by Drug Class

  • 6.1 Overview
  • 6.2 Anti-Viral
    • 6.2.1 Overview
    • 6.2.2 Anti-viral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Anti-bacterial
    • 6.3.1 Overview
    • 6.3.2 Anti-bacterial: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Anti-fungal
    • 6.4.1 Overview
    • 6.4.2 Anti-fungal: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Infectious Disease Therapeutics Market Analysis - by Indication

  • 7.1 Overview
  • 7.2 HIV
    • 7.2.1 Overview
    • 7.2.2 HIV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Hepatitis
    • 7.3.1 Overview
    • 7.3.2 Hepatitis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Tuberculosis
    • 7.4.1 Overview
    • 7.4.2 Tuberculosis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Influenza
    • 7.5.1 Overview
    • 7.5.2 Influenza: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 HPV
    • 7.6.1 Overview
    • 7.6.2 HPV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Infectious Disease Therapeutics Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Topical
    • 8.4.1 Overview
    • 8.4.2 Topical: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Infectious Disease Therapeutics Market Analysis - by Distribution Channel

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Hospital Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Retail Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Retail Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Infectious Disease Therapeutics Market - Country Analysis

  • 10.1 Europe Infectious Disease Therapeutics Market
    • 10.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 Overview
      • 10.1.1.3 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 Germany: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.3.2 Germany: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.3.3 Germany: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.3.4 Germany: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.4 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Overview
      • 10.1.1.5 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.1 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.5.2 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.5.3 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.5.4 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.6 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Overview
      • 10.1.1.7 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.7.1 France: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.7.2 France: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.7.3 France: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.7.4 France: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.8 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.8.1 Overview
      • 10.1.1.9 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.9.1 Italy: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.9.2 Italy: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.9.3 Italy: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
        • 10.1.1.9.4 Italy: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.10 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.10.1 Overview
      • 10.1.1.11 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.11.1 Spain: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.11.2 Spain: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.11.3 Spain: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.11.4 Spain: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.12 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.12.1 Overview
      • 10.1.1.13 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.13.1 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.13.2 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.13.3 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.13.4 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Infectious Disease Therapeutics Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Infectious Disease Therapeutics Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Pfizer Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Gilead Sciences Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 F. Hoffmann-La Roche Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Shionogi & Co Ltd
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Bayer AG
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 BioCryst Pharmaceuticals Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 GSK Plc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 AbbVie Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Merck & Co Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Astellas Pharma Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners

List Of Tables

  • Table 1. Europe Infectious Disease Therapeutics Market Segmentation
  • Table 2. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
  • Table 3. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
  • Table 4. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 5. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 6. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 7. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 8. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 9. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 10. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 11. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 12. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 13. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 14. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 15. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 16. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 17. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 18. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 19. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 20. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 21. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration
  • Table 22. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 23. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 24. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 25. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 26. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 27. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 28. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 29. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 30. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 31. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
  • Table 32. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market

List Of Figures

  • Figure 1. Europe Infectious Disease Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Europe Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
  • Figure 4. Europe Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
  • Figure 5. Anti-viral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Anti-bacterial: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Anti-fungal: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Europe Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
  • Figure 10. HIV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Hepatitis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Tuberculosis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Influenza: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. HPV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Europe Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
  • Figure 17. Oral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Parenteral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Topical: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Europe Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Europe Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. Europe Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 31. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 32. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 33. Growth Strategies in the Infectious Disease Therapeutics Market